Inegy (Simvastatin, Ezetimibe)

The combination works on two pathways: simvastatin inhibits HMG‑CoA reductase, the key enzyme for hepatic cholesterol synthesis, while ezetimibe blocks the NPC1L1 transporter in the intestine, reducing absorption of dietary and biliary cholesterol. Together they lower the amount of cholesterol reaching the liver, prompting up‑regulation of LDL receptors and increased clearance of circulating LDL‑C.

The appropriate dose of Inegy is determined by the prescribing healthcare professional based on the patient’s clinical condition, lipid profile, and response to therapy. Dosage may be adjusted after evaluating efficacy and tolerability, and patients should follow the prescriber’s specific instructions without deviation.

Data on the use of simvastatin/ezetimibe during pregnancy and lactation are limited, and potential risks to the fetus or infant cannot be excluded. Consequently, the product is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk, and a prescriber should evaluate each case individually.

To request Inegy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Inegy combines a statin (simvastatin) with a cholesterol absorption inhibitor (ezetimibe), offering greater LDL‑C reduction than a statin alone for many patients. This dual mechanism can be advantageous when statin monotherapy does not achieve target lipid levels, while maintaining a similar safety profile to each component used individually.

Inegy tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and store out of reach of children. Do not refrigerate or freeze the product.

Inegy is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a full glass of water. Patients should not crush, split, or chew the tablet unless specifically instructed.

The most serious adverse events include rhabdomyolysis (muscle breakdown that can lead to kidney injury), severe liver injury, acute renal failure, and anaphylactic reactions. Patients should promptly report unexplained muscle pain, weakness, dark urine, jaundice, or signs of an allergic reaction such as swelling or difficulty breathing.

Inegy is contraindicated in patients with active liver disease, persistent elevations of hepatic transaminases, known hypersensitivity to simvastatin, ezetimibe, or any excipients, and in individuals taking strong CYP3A4 inhibitors that cannot be discontinued. Caution is also advised for patients with severe renal impairment or those on interacting medications.